Please login to the form below

Not currently logged in
Email:
Password:

Ninlaro

This page shows the latest Ninlaro news and features for those working in and with pharma, biotech and healthcare.

Immunology keeps Shire figures solid as Takeda takeover nears

Immunology keeps Shire figures solid as Takeda takeover nears

There were gains for newer products Entyvio (vedolizumab) or ulcerative colitis, up a third to around $550m, and myeloma therapy Ninlaro (ixazomib) which climbed 43% to $125m, but Takeda is predicting

Latest news

  • Takeda can't sway NICE on oral myeloma therapy Ninlaro Takeda can't sway NICE on oral myeloma therapy Ninlaro

    Takeda can't sway NICE on oral myeloma therapy Ninlaro. Drug not recommended for NHS use in England and Wales. ... Ninlaro was approved by the EMA last November, becoming the first orally-active proteasome inhibitor to be registered in Europe.

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    The proteasome inhibitor category has also experienced a shake-up with the launch of Takeda's Ninlaro (ixazomib), the first orally-active drug in the class.

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    Takeda's orally-active proteasome inhibitor Ninlaro (ixazomib), Novartis' HDAC inhibitor Farydak (panobinostat) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) are all jostling for market share with Darzalex at

  • Takeda gets EU green light for oral myeloma drug Takeda gets EU green light for oral myeloma drug

    Takeda gets EU green light for oral myeloma drug. Ninlaro first oral proteasome inhibitor to be registered in Europe. ... Ninlaro is already available in the US, Canada, Israel, Australia and Venezuela, and has been filed in other markets including Japan.

  • Celgene’s Revlimid cleared for aggressive lymphoma type in EU Celgene’s Revlimid cleared for aggressive lymphoma type in EU

    Some new drugs like Takeda's oral proteasome inhibitor therapy Ninlaro (ixazomib) have been approved for use in combination with Celgene's drug, but analysts suggest Revlimid could see direct competition

More from news
Approximately 4 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics